Drug intelligence / Profile preview

DN-2025001

Development stage: Preclinical
Lead developer: Daehan Nupharm
Modality: Small Molecules

Overview

DN-2025001 is a small molecule analgesic candidate currently in development by Daehan Nupharm, a South Korean pharmaceutical company. The drug is being investigated for its potential in pain management. As an early-stage pipeline asset, specific pharmacological details such as its molecular target or precise mechanism of action remain proprietary or are in the early stages of characterization. It represents part of Daehan Nupharm's strategic effort to expand its therapeutic portfolio in the analgesic and central nervous system space.

Beyond the preview

Go deeper on DN-2025001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DN-2025001.

Explore the full profile